Jefferies analyst Andrew Tsai lowered Rocket Pharmaceuticals' price target to $2.95, with shares trading at $2.48. The company is advancing its gene therapy for Danon disease, RP-A501, with an FDA-aligned pivotal study plan. Rocket secured $35 million in funding, extending its cash runway into Q3 2028, potentially longer with more borrowing. This funding supports ongoing development of treatments for rare diseases, though no trial results were disclosed yet.
Rocket Pharmaceuticals' recent funding of $35 million extends its cash runway into Q3 2028. For readers following the health sector, here is Pluang's market snapshot as of Oct 07, 2026 20:05 WIB: out of 100 priced US health stocks, 46 rose and 50 fell. Notable movers include Heron Therapeutics Inc (HRTX) up 2.50% at USD 0.34 with 54% sell order activity, Mesoblast Limited (MESO) up 2.35% at USD 13.93, and Danaher Corporation (DHR) up 2.06% at USD 220.01.
Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...
Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...
Barclays has lowered its price target for Netflix shares from $80 to $70 due to concerns over slower revenue growth and rising content costs, especially for live programming. Despite Netflix's large subscriber base of 325 million, the company faces p...
Granada Gold Mine Inc. has applied for drilling permits to expand its mineral resources at the Granada Gold Project near Rouyn-Noranda, Quebec. The project has historical drilling data covering about 20% of the property, with significant gold resourc...
Calnex Solutions and VIAVI Solutions have expanded their strategic partnership to combine Calnex's network emulation tools with VIAVI's traffic generation and testing solutions. This collaboration enables customers to simulate real-world network cond...
